期刊文献+

HA纳米载体转hGM-CSF基因的HepG2疫苗的抗肿瘤活性研究 被引量:2

The Anti-Tumor Activity of HepG2 Tumor Vaccine Transfected hGM-CSF Gene Mediated by HA Nanoparticles
原文传递
导出
摘要 目的:评价HA纳米载体转hGM-CSF基因的HepG2疫苗的抗肿瘤活性。方法:SCID小鼠20只腹腔内注射健康志愿者外周血淋巴细胞(1×107/ml)1.0 ml,同时背部皮下接种人肝癌HepG2细胞(1×107ml)0.2 ml。当皮下移植瘤体积长至100 mm3时,随机分四组:Ⅰ组,60Co照射的转染GM-CSF基因的HepG2细胞组,Ⅱ组,60Co照射的HepG2细胞组,Ⅲ组,生理盐水组,Ⅳ组,接种前,每组5只。MTT法检测各组小鼠脾细胞CTL活性,ELISA法检测血清IL-4和IL-12的水平。结果:转染GM-CSF基因的HepG2疫苗组小鼠脾细胞CTL活性明显高于其余组(P<0.05);同时血清Th1类细胞因子IL-12的水平明显升高(P<0.05),而Th2类细胞因子IL-4的水平无统计学意义(P>0.05)。结论:HA纳米载体转hGM-CSF基因的HepG2疫苗可刺激机体产生特异性免疫反应。 Objective: To investigate the anti-tumor effects and mechanism of HepG2 tumor vaccine transfected hGM-CSF gene mediated by HA nanoparticles.Methods: Health human peripheral blood lymphocytes were isolated from peripheral blood of healthy donors and intraperitoneal injected into SCID mice at 2×10&7/ ml.Simultaneously,hepatocellular carcinoma cells were intracutaneously injected into SCID mouse at 2×10^7/ ml.When the xenografted to a 100 mm3,mice was randomly divided into 4 groups: Group 1,HepG2 cells transfected with GM-CSF Gene after 60Co irradiation group;Group 2,HepG2 cells after 60Co irradiation group;Group 3,normal saline group: Group 4,uninjected group.Every group had 5 mice.Cytotoxic rates were detected by using MTT assay.The level of IL-12 and IL-4 in serum was detected by ELISA method.Results: The activaty of CTL were significantly higher in group HepG2 tumor vaccine transfected hGM-CSF gene mediated by HA nanoparticles than those in other groups(P〈0.05);Serum level of Th1-type cytokine IL-12 increased after vaccination(P〈0.05),whereas Th2-type cytokine IL-4 showed no significant changes(P〉0.05).Conclusion: The HepG2 tumor vaccine transfected hGM-CSF gene mediated by HA nanoparticles can induce immune response.
出处 《现代生物医学进展》 CAS 2012年第10期1824-1827,共4页 Progress in Modern Biomedicine
基金 湖南省卫生厅科研基金资助项目(B2005-178)
关键词 肝癌 HA纳米载体 GM-CSF基因 肿瘤疫苗 Hu-PBL-SCID小鼠 Hepatoma carcinoma Nano-hydroxyapatite vector GM-CSF gene Tumor vaccine Hu-PBL-SCID mouse
  • 相关文献

参考文献21

  • 1Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity [J]. Proc Natl Acad Sci USA,1993,90 (9):3 539-3543.
  • 2曾治中,段晓明,程元星,黄璐,贺修胜.HA纳米载体介导转hGM-CSF基因的HepG2疫苗诱导的抗瘤效应研究[J].现代生物医学进展,2011,11(4):672-676. 被引量:2
  • 3Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating fator by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma [J]. J Clin Oncol,2003,21:3343-3350.
  • 4Tanii K, Azuma M, Nakazaki Y, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage Ⅳ renal cell cancer in Japan:clinical and immunological findings[J]. Mol Ther,2004,10:799-816.
  • 5Nemunaitis J, Sterman D, Jablon D, et al. Granulocyte-macrophage colony-stimulating fator gene-modified autologous tumor vaccines in non-small-cell lung cancer[J]. J Natl Cancer Inst,2004,96:326-331.
  • 6张维红,姜宏景,马明全,李慧,于津浦,任秀宝.GM-CSF基因修饰同种异体肺癌细胞疫苗诱导CD8^+ T细胞的免疫反应[J].免疫学杂志,2008,24(5):545-548. 被引量:5
  • 7殷晓煜,黄嘉凌,吕明德,梁力建,周才明,黄洁夫.SCID鼠人肝癌皮下移植及免疫重建复合模型的建立[J].中华肝胆外科杂志,2004,10(3):184-186. 被引量:4
  • 8郭淦华,段晓明,刘晓宇,曹建国,贺修胜.羟基磷灰石纳米颗粒载体介导hGM-CSF基因转染HepG2细胞及对其生长的影响[J].肿瘤,2008,28(3):224-227. 被引量:12
  • 9Nagai H, Miyaki D, Mastsui T, et al. Th1/Th2 balance.an important indicator of efficacy for intra-arterial chemotherapy [J]. Cancer Chem other Phamacol,2008,62(6):959-963.
  • 10Sharma A, Rajappa M, Satyam A, et al. Cytokines (TH1 and TH2) in patientswith advanced cervical cancerundergoing neoad-juvant chemoradiation: correlationwith treatment response[J]. IntJGyneeolCancer, 2009,19(7):1269-1275.

二级参考文献43

  • 1朱晒红,周科朝,黄伯云,黄苏萍,刘芳,李益民,薛志刚,龙志高.羟基磷灰石纳米颗粒:一种新型基因转染载体材料[J].生物医学工程学杂志,2005,22(5):980-984. 被引量:23
  • 2Wakai, T., et al., Hepatitis viral status affects the pattern of intrahepatic recurrence after resection for hepatocellular carcinoma [J]. Eur J Surg Oncol, 2003, 29(3): 266-71.
  • 3Tepper RI, Mule JJ. Experimental and clinical studies ofeytokine gene2modified tumor cells[J].Hum Gene Ther, 1994,5(2): 153-164.
  • 4Pardoll DM. Paracrine cytokine adjuvants in caneerimmunotherapy. [J]. Annu Rev Immunol, 1995, 13:339-415.
  • 5Morita T, Ikeda K, Douzona M, et al. Tumor Vaccination withmacrophage colony-stimulating factor producing Lewis lungcarcinoma in mice[J]. Blood, 1996,88(3):955-961.
  • 6Ulmer, J.B., B. Wahren, and M.A. Liu, Gene-based vaccines: recent technical and clinical advances [J]. Trends Mol Med, 2006, 12(5): 216-22.
  • 7Hege, K.M., K. Jooss, and D. Pardoll, GM-CSF gene-modifed cancer cell immunotherapies: of mice and men [J]. Int Rev Immunol, 2006, 25(5-6): 321-52.
  • 8Eager, R. and J. Nemtmaitis, GM-CSF gene-transduced tumor vaccines [J]. Mol Ther, 2005,12(1): 18-27.
  • 9Soiffer, R., et al., Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colonystimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma [J]. J Clin Oncol, 2003, 21(17): 3343-50.
  • 10Simons, J.W., et al. Phase Ⅰ/Ⅱ trial of an allogeneic cellular im-munotherapy in hormone-naive prostate cancer [J]. Clin Cancer Res, 2006, 12(11 Pt 1): 3394-401.

共引文献16

同被引文献13

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部